Lucira Health announced that the U.S. Food and Drug Administration granted emergency use authorization for its Lucira COVID-19 & Flu Home Test for over the counter use at home and other non-laboratory sites. The Lucira COVID-19 & Flu Home Test is a molecular test that demonstrated similar performance for COVID-19 and Influenza A and B compared to highly sensitive lab-based PCR tests in clinical trials. Lucira’s COVID-19 & Flu Home Test represents a breakthrough in diagnostic testing as the first at-home combination COVID-19 and Flu test, and as the first Flu test for OTC use at home in the United States in history. Until today, American consumers have never before been able to self-diagnose Flu at home. The easy-to-use, all-in-one combination test delivers results in 30 minutes or less from one shallow nasal swab.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on LHDX:
- Lucira Soars on FDA Approval of COVID-19 and Flu Test
- Lucira Health to pursue sale through Chapter 11
- Lucira Health to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process
- Lucira Health names Richard Narido as CFO
- Lucira Health partners with Sesame for COVID-19 telehealth experience